Alivus Life Sciences Limited (NSEI: ALIVUS)
Health Care · Pharmaceuticals · IN
Rs1,374.20
+0.63% today · +47.2% 1Y
Alivus Life Sciences Limited (NSEI: ALIVUS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.75B and employs 2,272 people.
Over the last twelve months the share price has gained 47.2%, trading between 819.00 and 1.49K.
Tweenvest scores Alivus Life Sciences Limited across four factors: quality 73/100, value 18/100, growth 48/100, dividend 62/100. Its strongest factor is quality.
ALIVUS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.75B
- Revenue (TTM)
- $273.97M
- P/E
- 28.03
- EPS
- 49.03
- Dividend yield
- 0.36%
- Beta (5Y)
- 0.07
- 52-week high
- Rs1,493.80
- 52-week low
- Rs819.00
- Avg volume (3M)
- —
- Shares outstanding
- 122.74M
- Employees
- 2,272
- Next earnings
- —
About Alivus Life Sciences Limited
Alivus Life Sciences Limited, a Mumbai, India-headquartered entity established in 2001, operates as a subsidiary of Nirma Limited. Having rebranded from Glenmark Life Sciences Limited in December 2024, the company specializes in the development, production, and global commercialization of active pharmaceutical ingredients (APIs). Its market footprint spans India, Japan, Europe, and both North and Latin America, supported by substantial export operations. Alivus Life Sciences provides an extensive catalog of APIs, including olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib. These ingredients are utilized across a diverse array of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppression, respiratory and ophthalmological conditions, urology, and anti-infectives. Additionally, the company extends its expertise by offering contract development and manufacturing services (CDMO) to numerous multinational corporations and specialty pharmaceutical enterprises.
- ISIN
- INE03Q201024
- Founded
- 2001
- Listed since
- Aug 6, 2021
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Cohance Lifesciences LimitedNSEI: COHANCE | $1.79B | Rs451.30 | -1.73% |
| Neuren Pharmaceuticals LimitedASX: NEU | $1.79B | AU$20.28 | +0.30% |
| Septerna, Inc.NasdaqGM: SEPN | $1.76B | $36.90 | -2.15% |
| Zhejiang Medicine Co., Ltd.SHSE: 600216 | $1.76B | CN¥12.43 | +0.81% |
| Tsumura & Co.TSE: 4540 | $1.75B | ¥3,703.00 | -4.51% |
| Hanall Biopharma Co., Ltd.KOSE: A009420 | $1.74B | ₩46,100.00 | -1.07% |
| Eris Lifesciences LimitedNSEI: ERIS | $1.71B | Rs1,189.80 | -5.49% |
| Bora Pharmaceuticals Co., Ltd.TWSE: 6472 | $1.68B | NT$420.50 | -0.24% |
Figures last refreshed Oct 4, 2026.